Xiao Hua, Bao Yu, Liu Ming-Yue, Yang Jun-Hua, Li Yan-Ting, Wang Yi-An, Wang Ying, Yan Yue, Zhu Zhu, Ni Mei, Huang Xiao-Yan, Tian Xin-Kui, Wang Tao, Zhe Xing-Wei
Division of Nephrology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, Yunnan province, China.
Division of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.
Int Urol Nephrol. 2018 Sep;50(9):1679-1685. doi: 10.1007/s11255-018-1861-6. Epub 2018 Apr 12.
Chronic kidney disease (CKD) is very common now and is associated with high overall and cardiovascular mortality. Numerous studies have reported that abdominal obesity is a risk factor for cardiovascular mortality. We investigated the link between sagittal abdominal diameter (SAD) and Framingham risk score in non-dialysis CKD patients.
In a cross-sectional study, we enrolled 307 prevalent non-dialysis CKD patients (175 males, aged 50.7 ± 17.04 years). SAD and Framingham risk score were measured.
Framingham cardiovascular disease risk score was independently predicted by SAD (P < 0.01), GFR (P < 0.01) and diabetic history (P < 0.05). Adjusted R of the model was 0.178. SAD could be independently predicted by BMI (P < 0.01), diabetic history (P < 0.01), GFR (P < 0.01) and age (P < 0.01). Adjusted R of the model was 0.409. Using receiver operating characteristic (ROC) curve, a cutoff SAD value of 16.55 cm was determined with sensitivity of 63.7%, specificity of 58.3%.
Elevated SAD is significantly associated with increased Framingham risk score in non-dialysis CKD patients. SAD can be predicted by patients' BMI, diabetic history, renal function and age. Further investigation is needed to explore the potential benefits of central obesity lowering therapy in this patient group.
慢性肾脏病(CKD)目前非常常见,且与总体及心血管疾病高死亡率相关。众多研究报道腹型肥胖是心血管疾病死亡的一个危险因素。我们调查了非透析CKD患者的腹围矢状径(SAD)与弗雷明汉风险评分之间的联系。
在一项横断面研究中,我们纳入了307例非透析CKD患者(175例男性,年龄50.7±17.04岁)。测量了SAD和弗雷明汉风险评分。
弗雷明汉心血管疾病风险评分由SAD(P<0.01)、肾小球滤过率(GFR)(P<0.01)和糖尿病史(P<0.05)独立预测。该模型的调整R值为0.178。SAD可由体重指数(BMI)(P<0.01)、糖尿病史(P<0.01)、GFR(P<0.01)和年龄(P<0.01)独立预测。该模型的调整R值为0.409。使用受试者工作特征(ROC)曲线,确定SAD的截断值为16.55cm,敏感性为63.7%,特异性为58.3%。
在非透析CKD患者中,升高的SAD与弗雷明汉风险评分增加显著相关。SAD可由患者的BMI、糖尿病史、肾功能和年龄预测。需要进一步研究以探索该患者群体中降低中心性肥胖治疗的潜在益处。